Study of 25,661 UK healthcare workers (including 8,278 with past COVID-19), showing past infection offers 84% protection against reinfection (93% for symptomatic disease) over 1-7 months. The emergence of the UK variant didn’t make reinfection more likely.
thelancet.com/journals/lance…
During the study, participants had a PCR test every 2 weeks, and an antibody test every 4 weeks, so we can be reasonably sure the majority of cases would have been detected.
There were 1,704 infections in people who hadn’t previously had COVID-19 (of which 17% were asymptomatic), and 2 probable and 153 possible reinfections (1.9%), of which 49% were asymptomatic.
The researchers were generally unable to perform genomic sequencing, and as such could not confirm the reinfections were genuine. Some probably reflect persistent viral shedding. This means their estimate of protection (84%) is probably an underestimate.
Healthcare workers are also a high-risk population, and may be exposed to the virus more often and in higher amounts. The rate of reinfection may therefore be lower in the general population.
However, the participants in this study were generally young (median age: 46 years; range: 18-84 years; IQR: 35-54 years). Older people (whose immune response may be less effective) might be less well protected.
In summary most people who’ve had COVID-19 are probably protected from reinfection over the short to medium term. However, vaccination remains the best way to protect yourself.

Those who’ve had COVID-19 should also get vaccinated to ensure they’re protected as much as possible.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Dr Zoë Hyde

Dr Zoë Hyde Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DrZoeHyde

11 Apr
Study of the Pfizer-BNT vaccine in 100 nursing home residents (64 with past COVID-19) & 15 healthcare workers.

A good antibody response was detected in 97% with past COVID-19, 93% of healthcare workers, but only 61% of residents who’d never been infected.
academic.oup.com/cid/advance-ar…
A similar pattern was found with regard to cellular immunity.

A good response was found in 97% of residents with past COVID-19, and in 87% of healthcare workers, but only 48% of residents who’d never been infected.
This study was done 4 weeks after the first vaccine dose.

It’s unclear if the results indicate that older people may take longer to have a good response to the vaccine, or if it is less effective in older people.

If the latter, attaining herd immunity becomes more important.
Read 5 tweets
5 Apr
(1/12) The Brazilian #COVID19 variant is up to 2 times more transmissible, more likely to cause serious illness in young people, and may evade immunity.

Worryingly, it’s starting to spread rapidly in British Columbia, Canada. 🇨🇦

A thread summarising the latest evidence. 🧵
(2/12) Previous research suggested the variant was 40 to 120% more transmissible, and may be able to reinfect people more easily.

Mortality appeared 10 to 80% higher, although it was unclear if this reflected hospitals being overwhelmed with cases.
(3/12) Two new pre-print studies (interpret them carefully) provide more evidence the variant is more virulent.

A study conducted in Brazil’s Amazonas state found that women and young people were more seriously affected once the variant became common.
Read 12 tweets
2 Apr
The California variant (B.1.427/B.1.429), appears more transmissible and possibly more virulent (but less than the UK variant).

Concerning new data suggest vaccine efficacy against symptomatic disease might be reduced (though probably not as much as the South African variant).
However, vaccines have better efficacy against severe disease than mild-to-moderate disease.

It’s therefore likely that efficacy against severe disease will be largely preserved, but we may see reduced protection with regard to transmission.
There is also the potential for reinfections to be more common with this variant, particularly for people who had only very mild COVID-19, and did not develop much in the way of neutralising antibodies.
Read 4 tweets
1 Apr
Updated Pfizer results have been released.

➡️ 91% (95% CI 89-93%) efficacy against symptomatic infection.

➡️ 100% (88-100%) efficacy against severe disease as per the CDC definition (based on 32 cases); 95% (71-99%) efficacy as per FDA definition (22 cases, 1 in vaccine group).
Additionally, Pfizer also reported data from South Africa, in which 800 people received the vaccine.

Nine cases were detected in the placebo group, 6 of which were the South African variant.

No cases were detected in the vaccine group.
This provides tentative evidence that the Pfizer vaccine may be effective against the South African variant, although the confidence interval is wide (53-100%).

Link to announcement: pfizer.com/news/press-rel…
Read 4 tweets
1 Apr
Today, the UK’s Office for National Statistics released an enormously important report on long COVID.

The data now have a control group.

Over 1 in 10 people (14%) have persistent symptoms at 12 weeks. This is 8x higher than controls.

Look at the children’s data: 7-8% affected!
We can clearly see the difference between people who have long COVID, and people who are controls, in this graph showing the proportion of people with persistent symptoms at the 5-week mark.

Blue = tested positive.
Green = controls.
The proportion of people who had persistent symptoms was lower at 12 weeks, which suggests improvement in many people.

This is to be expected.

However, a substantial proportion of people appear to be left with protracted symptoms.
Read 5 tweets
30 Mar
It's increasingly clear this is a real & very serious adverse effect.

In much of the world, use of the AstraZeneca vaccine still makes sense. The benefits still outweigh the risks.

That's not the case in Australia, and we should pivot to an alternative vaccine. #auspol
Australia doesn't have widespread community transmission. That means the AstraZeneca vaccine could harm more people than it helps - at this point in time.

This picture could of course change, if Australia were to experience a major wave.
But what about Europe, or the Americas? A case could be made for continuing to use the vaccine, but restricting its use to older age groups, who seem less likely to experience this adverse effect.

This is now the case in France or Germany.
Read 6 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!